Result of AGM

RNS Number : 7885C

N4 Pharma PLC

19 June 2019

 

19 June 2019

N4 Pharma Plc

("N4 Pharma" or the "Company")

Result of AGM

N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for vaccines and cancer treatments, announces that at its annual general meeting ("AGM"), held earlier today, all resolutions were duly passed. All resolutions were passed on a show of hands.  The results of the proxy voting for the AGM is set out below.

	Resolution	Total votes For1	% of votes cast2	Total Votes Against	% of votes cast2	Total Votes Cast3	% of issued share capital	Votes Withheld4
1	To receive the annual report and audited accounts for the year ended 31 December 2018	16,362,457	99.99	1,134	0.01	16,363,591	16.13	0
2	To re-elect Luke Cairns as a director of the Company	16,332,857	99.99	1,134	0.01	16,333,991	16.10	29,600
3	To elect John Chiplin as a Director of the Company	16,332,857	99.99	1,134	0.01	16,333,991	16.10	29,600
4	To elect Chris Britten as a Director of the Company	16,332,857	99.99	1,134	0.01	16,333,991	16.10	29,600
5	To re-appoint Saffery Champness LLP as auditor and authorise directors to determine their remuneration	16,334,857	99.85	25,000	0.15	16,359,857	16.12	3,734
6	Authority to allot shares	16,331,657	99.82	30,200	0.18	16,361,857	16.12	1.734
7	Authority to disapply pre-emption rights	16,330,457	99.97	5,334	0.03	16,335,791	16.10	27,800

Notes:

1.             Any proxy votes that were at the discretion of the Chairman are included in the "Total Votes For" each resolution

2.             Percentage of votes cast excludes Votes Withheld

3.             Total Votes Cast do not include withheld votes

4.             Votes Withheld are not votes in law and do not count in the number of votes counted for or against a resolution

Enquiries:

N4 Pharma Plc Nigel Theobald, CEO	Via Scott PR
Allenby Capital Limited James Reeve/Asha Chotai	Tel: [phone]
Scott PR Georgia Smith	Tel: [phone]

About N4 Pharma

N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for vaccines and cancer treatments using its unique silica nanoparticle delivery system called Nuvec®.

N4 Pharma's business model is to partner with companies developing novel antigens for vaccines and cancer treatments to use Nuvec® as the delivery vehicle to get their antigen into cells to express the protein needed for the required immunity. As these products progress through pre clinical and clinical programs, N4 Pharma will seek to receive up front payments, milestone payments and ultimately royalty payments once products reach the market.

 

END

 

 

RAGBBGDLGUBBGCC